1084-12-4

Usage

Uses

Used in Organic Synthesis:
N-(5-bromopyridin-3-yl)benzenesulfonamide is used as a building block in organic synthesis for its ability to facilitate the creation of new molecules with desired biological properties. Its unique structure and reactivity make it a key component in the synthesis of various organic compounds.
Used in Drug Development:
In the pharmaceutical industry, N-(5-bromopyridin-3-yl)benzenesulfonamide is utilized as a starting material for drug development. Its potential antifungal, antiviral, and anti-inflammatory properties make it a promising candidate for the development of new therapeutic agents.
Used in Chemical Modifications:
The bromopyridine moiety in N-(5-bromopyridin-3-yl)benzenesulfonamide serves as a versatile handle for various chemical modifications. This feature is exploited in the synthesis of diverse compounds, enhancing the compound's applicability in different pharmaceutical applications.
Used in Antifungal Applications:
N-(5-bromopyridin-3-yl)benzenesulfonamide is used as an antifungal agent due to its potential to combat fungal infections, providing a valuable tool in the development of new antifungal medications.
Used in Antiviral Applications:
In antiviral applications, N-(5-bromopyridin-3-yl)benzenesulfonamide is employed for its potential to inhibit viral replication and activity, making it a candidate for the development of antiviral drugs.
Used in Anti-inflammatory Applications:
N-(5-bromopyridin-3-yl)benzenesulfonamide is also used as an anti-inflammatory agent, leveraging its potential to reduce inflammation and alleviate symptoms associated with inflammatory conditions.

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 98-09-9 benzenesulfonyl chloride 
• 1192749-74-8 N-(5-bromopyridin-3-yl)-N-(phenylsulfonyl)benzenesulfonamide 

Downstream Products

• 1083326-28-6 N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-benzenesulfonamide 
• 1198803-16-5 N-{5-[4-amino-1-(phenylsulfonyl)-1H-indazol-6-yl]-3-pyridinyl}benzenesulfonamide 
• 1276109-91-1 N-(5-(3-pyridyl)pyridin-3-yl)benzenesulfonamide 
• 1276109-93-3 N-(5-(4-pyridyl)pyridin-3-yl)benzenesulfonamide 
• 1276110-12-3 N-(5-(3-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-benzenesulfonamide 
• 1276110-15-6 N-(5-(3-phenylimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-06-5 ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]-pyridine-3-carboxylate 
• 1276110-04-3 N-(5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1261082-75-0 N-(5-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyridin-3-yl)benzenesulfonamide 
• 1276109-95-5 N-(5-(2-aminopyrimidin-5-yl)pyridin-3-yl)benzenesulfonamide 
• 1276109-98-8 N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1351597-79-9 C₁₇H₁₇N₅O₂S 
• 1351597-82-4 C₁₆H₁₅N₅O₂S 
• 1351597-83-5 C₁₇H₁₇N₅O₂S 

Relevant academic research and scientific papers

Prospective evaluation and success of a machine learning hit-to-lead drug development program against phosphatidylinositol 3-kinase α

As a result of the rapidly increasing cost of drug development, efficient methods for early identification of compounds with a high probability of clinical success are needed. Herein, we describe a cheminformatics protocol which dramatically increases quality candidate identification and should reduce the attrition rate of compounds entering the clinic, increasing the cost-effectiveness of drug development. Against the oncology target phosphatidylinositol 3-kinase α, all five compounds synthesized from the protocol were found to have low nanomolar activity. We therefore propose that our protocol can be used as a tool for reducing the synthetic burden required for hit-to-lead optimization.

PHOSPHOTIDYLINOSITOL 3-KINASE INHIBITORS

This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.

Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity

The phosphoinositide 3-kinase (PI3K) inhibitors potently inhibit the signaling pathway of PI3K/AKT/mTOR, which provides a promising new approach for the molecularly targeted cancer therapy. In this work, a novel series of 7-azaindole scaffold derivatives was discovered by the fragment-based growing strategy. The structure-activity relationship profiles identified that the 7-azaindole scaffold derivatives exhibit potent activity against PI3K at molecular and cellular levels as well as cell proliferation in a panel of human tumor cells.

INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt path

NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis

Phosphatidylinositol 3-kinase α (PI3Kα) is an important regulator of intracellular signaling pathways, controlling remarkably diverse arrays of physiological processes. Because the PI3K pathway is frequently up-regulated in human cancers, the inhibition of PI3Kα can be a promising approach to cancer therapy. In this study, we have designed and synthesized a new series of imidazo[1,2-a]pyridine derivatives as PI3Kα inhibitors through the fragment-growing strategy. By varying groups at the 3- and 6-positions of imidazo[1,2-a]pyridines, we studied the structure-activity relationships (SAR) profiles and identified a series of potent PI3Kα inhibitors. Representative derivatives showed good activity in cellular proliferation and apoptosis assays. Moreover, these inhibitors exhibited noteworthy antiangiogenic activity.

BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.

Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα

Phosphatidylinositol-3-kinase beta (PI3Kβ) is an important therapeutic target in arterial thrombosis and special types of cancer. In this study, a new series of aminopyridine-based PI3Kβ selective inhibitors have been developed by the structure-based design strategy. When incorporated with the phenyl ring on sulfonamide moiety, aminopyrimidine analogs showed good potency on PI3Kβ and selectivity over PI3Kα. Intriguingly, replacement of phenyl group on sulfonamide with naphthyl group enhanced selectivity over PI3Kα while retaining submicromolar PI3Kβ potency. Molecular modeling suggests that increased PI3Kβ specificity is caused by the interaction with salt bridge (Lys782-Asp923) and Asp862 that creat a unique pocket in PI3Kβ. These results clearly provide useful insight in the design of new PI3Kβ inhibitors with high potency and selectivity.

AMINO TRIAZOLES AS PI3K INHIBITORS

The invention relates to compounds of formula (I) Said compounds are useful as protein kinase inhibitors, especially inhibitors of P13K, for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.